請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/15652
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 黃德富(Tur-Fu Huang) | |
dc.contributor.author | Shiu-Wen Huang | en |
dc.contributor.author | 黃綉文 | zh_TW |
dc.date.accessioned | 2021-06-07T17:49:26Z | - |
dc.date.copyright | 2013-03-04 | |
dc.date.issued | 2013 | |
dc.date.submitted | 2013-02-01 | |
dc.identifier.citation | Agarwal, A, Gupta, S, Sharma, RK (2005) Role of oxidative stress in female reproduction. Reprod Biol Endocrinol 3: 28.
Alitalo, K, Carmeliet, P (2002) Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 1(3): 219-227. Anakwenze, OA, Milby, AH, Gans, I, Stern, JJ, Levin, LS, Wapner, KL (2012) Foot and ankle infections: diagnosis and management. J Am Acad Orthop Surg 20(11): 684-693. Annetta, M, Maviglia, R, Proietti, R, Antonelli, M (2009) Use of corticosteroids in critically ill septic patients : a review of mechanisms of adrenal insufficiency in sepsis and treatment. Curr Drug Targets 10(9): 887-894. Avraham, HK, Lee, TH, Koh, Y, Kim, TA, Jiang, S, Sussman, M, Samarel, AM, Avraham, S (2003) Vascular endothelial growth factor regulates focal adhesion assembly in human brain microvascular endothelial cells through activation of the focal adhesion kinase and related adhesion focal tyrosine kinase. J Biol Chem 278(38): 36661-36668. Baigent, C, Blackwell, L, Collins, R, Emberson, J, Godwin, J, Peto, R, Buring, J, Hennekens, C, Kearney, P, Meade, T, Patrono, C, Roncaglioni, MC, Zanchetti, A (2009) Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373(9678): 1849-1860. Baronzio, G, Schwartz, L, Kiselevsky, M, Guais, A, Sanders, E, Milanesi, G, Baronzio, M, Freitas, I (2012) Tumor interstitial fluid as modulator of cancer inflammation, thrombosis, immunity and angiogenesis. Anticancer Res 32(2): 405-414. Barreiro, O, Martin, P, Gonzalez-Amaro, R, Sanchez-Madrid, F (2010) Molecular cues guiding inflammatory responses. Cardiovasc Res 86(2): 174-182. Belhassen, L, Pelle, G, Dubois-Rande, JL, Adnot, S (2003) Improved endothelial function by the thromboxane A2 receptor antagonist S 18886 in patients with coronary artery disease treated with aspirin. J Am Coll Cardiol 41(7): 1198-1204. Bergers, G, Benjamin, LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3(6): 401-410. Biondi, RM, Cheung, PC, Casamayor, A, Deak, M, Currie, RA, Alessi, DR (2000) Identification of a pocket in the PDK1 kinase domain that interacts with PIF and the C-terminal residues of PKA. EMBO J 19(5): 979-988. Blankenberg, S, Barbaux, S, Tiret, L (2003) Adhesion molecules and atherosclerosis. Atherosclerosis 170(2): 191-203. Blantz, RC, Munger, K (2002) Role of nitric oxide in inflammatory conditions. Nephron 90(4): 373-378. Bona, RD, Liuzzo, G, Pedicino, D, Crea, F (2011) Anti-inflammatory treatment of acute coronary syndromes. Curr Pharm Des 17(37): 4172-4189. Bondeson, J (1997) The mechanisms of action of disease-modifying antirheumatic drugs: a review with emphasis on macrophage signal transduction and the induction of proinflammatory cytokines. Gen Pharmacol 29(2): 127-150. Bousser, MG, Amarenco, P, Chamorro, A, Fisher, M, Ford, I, Fox, KM, Hennerici, MG, Mattle, HP, Rothwell, PM, de Cordoue, A, Fratacci, MD (2011) Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. Lancet 377(9782): 2013-2022. Bowles, DW, Kessler, ER, Jimeno, A (2011) Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib). Drugs of today 47(11): 857-868. Branen, L, Pettersson, L, Lindholm, M, Zaina, S (2001) A procedure for obtaining whole mount mouse aortas that allows atherosclerotic lesions to be quantified. Histochem J 33(4): 227-229. Brunton, VG, Frame, MC (2008) Src and focal adhesion kinase as therapeutic targets in cancer. Curr Opin Pharmacol 8(4): 427-432. Burns, RC, Rivera-Nieves, J, Moskaluk, CA, Matsumoto, S, Cominelli, F, Ley, K (2001) Antibody blockade of ICAM-1 and VCAM-1 ameliorates inflammation in the SAMP-1/Yit adoptive transfer model of Crohn's disease in mice. Gastroenterology 121(6): 1428-1436. Byrne, RA, Joner, M, Kastrati, A (2009) Polymer coatings and delayed arterial healing following drug-eluting stent implantation. Minerva Cardioangiol 57(5): 567-584. Cao, Y, Liu, Q (2007) Therapeutic targets of multiple angiogenic factors for the treatment of cancer and metastasis. Adv Cancer Res 97: 203-224. Capdeville, R, Buchdunger, E, Zimmermann, J, Matter, A (2002) Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 1(7): 493-502. Carmeliet, P (2005a) Angiogenesis in life, disease and medicine. Nature 438(7070): 932-936. Carmeliet, P (2005b) VEGF as a key mediator of angiogenesis in cancer. Oncology 69 Suppl 3: 4-10. Carmeliet, P, Jain, RK (2000) Angiogenesis in cancer and other diseases. Nature 407(6801): 249-257. Casscells, W (1992) Migration of smooth muscle and endothelial cells. Critical events in restenosis. Circulation 86(3): 723-729. Cayatte, AJ, Du, Y, Oliver-Krasinski, J, Lavielle, G, Verbeuren, TJ, Cohen, RA (2000) The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler Thromb Vasc Biol 20(7): 1724-1728. Celec, P (2004) Nuclear factor kappa B--molecular biomedicine: the next generation. Biomed Pharmacother 58(6-7): 365-371. Celletti, FL, Waugh, JM, Amabile, PG, Brendolan, A, Hilfiker, PR, Dake, MD (2001) Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 7(4): 425-429. Chalupka, AN, Talmor, D (2012) The economics of sepsis. Crit Care Clin 28(1): 57-76, vi. Chamorro, A (2009) TP receptor antagonism: a new concept in atherothrombosis and stroke prevention. Cerebrovasc Dis 27 Suppl 3: 20-27. Chan, ED, Riches, DW (2001) IFN-gamma + LPS induction of iNOS is modulated by ERK, JNK/SAPK, and p38(mapk) in a mouse macrophage cell line. Am J Physiol Cell Physiol 280(3): C441-450. Chen, KH, Reece, LM, Leary, JF (1999) Mitochondrial glutathione modulates TNF-alpha-induced endothelial cell dysfunction. Free Radic Biol Med 27(1-2): 100-109. Chow, LQ, Eckhardt, SG (2007) Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25(7): 884-896. Christensen, JG (2007) A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities. Ann Oncol 18 Suppl 10: x3-10. Chung, CH, Wu, WB, Huang, TF (2004) Aggretin, a snake venom-derived endothelial integrin alpha 2 beta 1 agonist, induces angiogenesis via expression of vascular endothelial growth factor. Blood 103(6): 2105-2113. Clowes, AW, Reidy, MA (1991) Prevention of stenosis after vascular reconstruction: pharmacologic control of intimal hyperplasia--a review. J Vasc Surg 13(6): 885-891. Cobb, MH, Goldsmith, EJ (2000) Dimerization in MAP-kinase signaling. Trends Biochem Sci 25(1): 7-9. Cohen, J (2002) The immunopathogenesis of sepsis. Nature 420(6917): 885-891. Cohen, MH, Gootenberg, J, Keegan, P, Pazdur, R (2007) FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 12(6): 713-718. Cook, KM, Figg, WD (2010) Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin 60(4): 222-243. Cooney, MM, van Heeckeren, W, Bhakta, S, Ortiz, J, Remick, SC (2006) Drug insight: vascular disrupting agents and angiogenesis--novel approaches for drug delivery. Nat Clin Pract Oncol 3(12): 682-692. Couto, JP, Almeida, A, Daly, L, Sobrinho-Simoes, M, Bromberg, JF, Soares, P (2012) AZD1480 Blocks Growth and Tumorigenesis of RET- Activated Thyroid Cancer Cell Lines. PloS one 7(10): e46869. Cyrus, T, Sung, S, Zhao, L, Funk, CD, Tang, S, Pratico, D (2002) Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice. Circulation 106(10): 1282-1287. Daemen, MJ (2008) Does atherosclerotic plaque histology predict the risk of restenosis after carotid endarterectomy? Nat Clin Pract Cardiovasc Med 5(8): 436-437. Dangas, G, Kuepper, F (2002) Cardiology patient page. Restenosis: repeat narrowing of a coronary artery: prevention and treatment. Circulation 105(22): 2586-2587. Davies, MG, Hagen, PO (1994) Pathobiology of intimal hyperplasia. Br J Surg 81(9): 1254-1269. Di Stefano, R, Felice, F, Balbarini, A (2009) Angiogenesis as risk factor for plaque vulnerability. Curr Pharm Des 15(10): 1095-1106. Dinarello, CA (2000) Proinflammatory cytokines. Chest 118(2): 503-508. Dogne, JM, de Leval, X, Hanson, J, Frederich, M, Lambermont, B, Ghuysen, A, Casini, A, Masereel, B, Ruan, KH, Pirotte, B, Kolh, P (2004) New developments on thromboxane and prostacyclin modulators part I: thromboxane modulators. Curr Med Chem 11(10): 1223-1241. Dogne, JM, Hanson, J, Pratico, D (2005) Thromboxane, prostacyclin and isoprostanes: therapeutic targets in atherogenesis. Trends Pharmacol Sci 26(12): 639-644. Doig, CJ, Laupland, KB, Zygun, DA, Manns, BJ (2003) The epidemiology of severe sepsis syndrome and its treatment with recombinant human activated protein C. Expert Opin Pharmacother 4(10): 1789-1799. Drevs, J, Siegert, P, Medinger, M, Mross, K, Strecker, R, Zirrgiebel, U, Harder, J, Blum, H, Robertson, J, Jurgensmeier, JM, Puchalski, TA, Young, H, Saunders, O, Unger, C (2007) Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 25(21): 3045-3054. Dvorak, HF (2005) Angiogenesis: update 2005. J Thromb Haemost 3(8): 1835-1842. Eikelboom, JW, Hirsh, J, Weitz, JI, Johnston, M, Yi, Q, Yusuf, S (2002) Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105(14): 1650-1655. Ekambaram, P, Lambiv, W, Cazzolli, R, Ashton, AW, Honn, KV (2011) The thromboxane synthase and receptor signaling pathway in cancer: an emerging paradigm in cancer progression and metastasis. Cancer Metastasis Rev 30(3-4): 397-408. Elice, F, Rodeghiero, F (2010) Bleeding complications of antiangiogenic therapy: pathogenetic mechanisms and clinical impact. Thromb Res 125 Suppl 2: S55-57. Elice, F, Rodeghiero, F Bleeding complications of antiangiogenic therapy: pathogenetic mechanisms and clinical impact. Thromb Res 125 Suppl 2: S55-57. Eliceiri, BP, Paul, R, Schwartzberg, PL, Hood, JD, Leng, J, Cheresh, DA (1999) Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol Cell 4(6): 915-924. Eliceiri, BP, Puente, XS, Hood, JD, Stupack, DG, Schlaepfer, DD, Huang, XZ, Sheppard, D, Cheresh, DA (2002) Src-mediated coupling of focal adhesion kinase to integrin alpha(v)beta5 in vascular endothelial growth factor signaling. J Cell Biol 157(1): 149-160. Eruslanov, E, Kusmartsev, S (2010) Identification of ROS using oxidized DCFDA and flow-cytometry. Methods Mol Biol 594: 57-72. Faivre, S, Delbaldo, C, Vera, K, Robert, C, Lozahic, S, Lassau, N, Bello, C, Deprimo, S, Brega, N, Massimini, G, Armand, JP, Scigalla, P, Raymond, E (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24(1): 25-35. Feldman, RI, Wu, JM, Polokoff, MA, Kochanny, MJ, Dinter, H, Zhu, D, Biroc, SL, Alicke, B, Bryant, J, Yuan, S, Buckman, BO, Lentz, D, Ferrer, M, Whitlow, M, Adler, M, Finster, S, Chang, Z, Arnaiz, DO (2005) Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem 280(20): 19867-19874. Feletou, M, Cohen, RA, Vanhoutte, PM, Verbeuren, TJ (2010a) TP receptors and oxidative stress hand in hand from endothelial dysfunction to atherosclerosis. Adv Pharmacol 60: 85-106. Feletou, M, Vanhoutte, PM, Verbeuren, TJ (2010b) The thromboxane/endoperoxide receptor (TP): the common villain. J Cardiovasc Pharmacol 55(4): 317-332. Feng, Q, Di, R, Tao, F, Chang, Z, Lu, S, Fan, W, Shan, C, Li, X, Yang, Z (2010) PDK1 regulates vascular remodeling and promotes epithelial-mesenchymal transition in cardiac development. Mol Cell Biol 30(14): 3711-3721. Ferrara, N (2004a) Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 9 Suppl 1: 2-10. Ferrara, N (2004b) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25(4): 581-611. Ferrara, N (2002) VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2(10): 795-803. Ferrara, N, Gerber, HP, LeCouter, J (2003) The biology of VEGF and its receptors. Nat Med 9(6): 669-676. Ferrara, N, Kerbel, RS (2005) Angiogenesis as a therapeutic target. Nature 438(7070): 967-974. Ferreiro, JL, Angiolillo, DJ (2012) New directions in antiplatelet therapy. Circ Cardiovasc Interv 5(3): 433-445. Finlay, DK, Rosenzweig, E, Sinclair, LV, Feijoo-Carnero, C, Hukelmann, JL, Rolf, J, Panteleyev, AA, Okkenhaug, K, Cantrell, DA (2012) PDK1 regulation of mTOR and hypoxia-inducible factor 1 integrate metabolism and migration of CD8+ T cells. J Exp Med 209(13): 2441-2453. Gabrielsen, A, Qiu, H, Back, M, Hamberg, M, Hemdahl, AL, Agardh, H, Folkersen, L, Swedenborg, J, Hedin, U, Paulsson-Berne, G, Haeggstrom, JZ, Hansson, GK (2010) Thromboxane synthase expression and thromboxane A2 production in the atherosclerotic lesion. J Mol Med 88(8): 795-806. Galley, HF (2011) Oxidative stress and mitochondrial dysfunction in sepsis. Br J Anaesth 107(1): 57-64. Giavazzi, R, Sennino, B, Coltrini, D, Garofalo, A, Dossi, R, Ronca, R, Tosatti, MP, Presta, M (2003) Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis. Am J Pathol 162(6): 1913-1926. Glaros, T, Larsen, M, Li, L (2009) Macrophages and fibroblasts during inflammation, tissue damage and organ injury. Front Biosci 14: 3988-3993. Gonzalez, ER (1998) Antiplatelet therapy in atherosclerotic cardiovascular disease. Clin Ther 20 Suppl B: B18-41. Gordon, S, Taylor, PR (2005) Monocyte and macrophage heterogeneity. Nat Rev Immunol 5(12): 953-964. Gross, PL, Weitz, JI (2009) New antithrombotic drugs. Clin Pharmacol Ther 86(2): 139-146. Gullestad, L, Ueland, T, Vinge, LE, Finsen, A, Yndestad, A, Aukrust, P (2012) Inflammatory cytokines in heart failure: mediators and markers. Cardiology 122(1): 23-35. Gum, PA, Kottke-Marchant, K, Welsh, PA, White, J, Topol, EJ (2003) A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41(6): 961-965. Hakim, J (1993) [Reactive oxygen species and inflammation]. C R Seances Soc Biol Fil 187(3): 286-295. Hamberg, M, Svensson, J, Wakabayashi, T, Samuelsson, B (1974) Isolation and structure of two prostaglandin endoperoxides that cause platelet aggregation. Proc Natl Acad Sci U S A 71(2): 345-349. Hansson, GK, Hermansson, A (2011) The immune system in atherosclerosis. Nat Immunol 12(3): 204-212. Hantschel, O, Grebien, F, Superti-Furga, G (2012) The Growing Arsenal of ATP-Competitive and Allosteric Inhibitors of BCR-ABL. Cancer research 72(19): 4890-4895. Harper, SJ, Bates, DO (2008) VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat Rev Cancer 8(11): 880-887. Hatada, EN, Krappmann, D, Scheidereit, C (2000) NF-kappaB and the innate immune response. Curr Opin Immunol 12(1): 52-58. Hennerici, MG (2009) Rationale and design of the Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin with Terutroban in Patients with a History of Ischemic Stroke or Transient Ischemic Attack (PERFORM) Study. Cerebrovasc Dis 27 Suppl 3: 28-32. Hennessy, BT, Smith, DL, Ram, PT, Lu, Y, Mills, GB (2005) Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4(12): 988-1004. Heo, SK, Yun, HJ, Noh, EK, Park, WH, Park, SD (2008) LPS induces inflammatory responses in human aortic vascular smooth muscle cells via Toll-like receptor 4 expression and nitric oxide production. Immunol Lett 120(1-2): 57-64. Hicklin, DJ, Ellis, LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23(5): 1011-1027. Hirata, M, Hayashi, Y, Ushikubi, F, Yokota, Y, Kageyama, R, Nakanishi, S, Narumiya, S (1991) Cloning and expression of cDNA for a human thromboxane A2 receptor. Nature 349(6310): 617-620. Hofstra, RM, Landsvater, RM, Ceccherini, I, Stulp, RP, Stelwagen, T, Luo, Y, Pasini, B, Hoppener, JW, van Amstel, HK, Romeo, G, et al. (1994) A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 367(6461): 375-376. Holash, J, Davis, S, Papadopoulos, N, Croll, SD, Ho, L, Russell, M, Boland, P, Leidich, R, Hylton, D, Burova, E, Ioffe, E, Huang, T, Radziejewski, C, Bailey, K, Fandl, JP, Daly, T, Wiegand, SJ, Yancopoulos, GD, Rudge, JS (2002) VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 99(17): 11393-11398. Holmes, K, Roberts, OL, Thomas, AM, Cross, MJ (2007) Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal 19(10): 2003-2012. Holmqvist, K, Cross, MJ, Rolny, C, Hagerkvist, R, Rahimi, N, Matsumoto, T, Claesson-Welsh, L, Welsh, M (2004) The adaptor protein shb binds to tyrosine 1175 in vascular endothelial growth factor (VEGF) receptor-2 and regulates VEGF-dependent cellular migration. J Biol Chem 279(21): 22267-22275. Hong, TT, Huang, J, Driscoll, E, Lucchesi, BR (2006) Preclinical evaluation of S18886 in an experimental model of coronary arterial thrombosis. J Cardiovasc Pharmacol 48(5): 239-248. Hori, A, Imaeda, Y, Kubo, K, Kusaka, M (2002) Novel benzimidazole derivatives selectively inhibit endothelial cell growth and suppress angiogenesis in vitro and in vivo. Cancer Lett 183(1): 53-60. Hsu, MJ, Cheng, JS, Huang, HC (2000) Effect of saikosaponin, a triterpene saponin, on apoptosis in lymphocytes: association with c-myc, p53, and bcl-2 mRNA. Br J Pharmacol 131(7): 1285-1293. Hu-Lowe, DD, Zou, HY, Grazzini, ML, Hallin, ME, Wickman, GR, Amundson, K, Chen, JH, Rewolinski, DA, Yamazaki, S, Wu, EY, McTigue, MA, Murray, BW, Kania, RS, O'Connor, P, Shalinsky, DR, Bender, SL (2008) Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 14(22): 7272-7283. Huang, SW, Lien, JC, Kuo, SC, Huang, TF (2012) Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling. Carcinogenesis 33(5): 1022-1030. Indolfi, C, Mongiardo, A, Curcio, A, Torella, D (2003) Molecular mechanisms of in-stent restenosis and approach to therapy with eluting stents. Trends Cardiovasc Med 13(4): 142-148. Inoue, T, Croce, K, Morooka, T, Sakuma, M, Node, K, Simon, DI (2011) Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis. JACC Cardiovasc Interv 4(10): 1057-1066. Ishizuka, T, Higashino, H (2006) TP receptor as a therapeutic target in atherosclerosis and related cardiovascular diseases. Recent Pat Cardiovasc Drug Discov 1(3): 241-247. Itokawa, T, Nokihara, H, Nishioka, Y, Sone, S, Iwamoto, Y, Yamada, Y, Cherrington, J, McMahon, G, Shibuya, M, Kuwano, M, Ono, M (2002) Antiangiogenic effect by SU5416 is partly attributable to inhibition of Flt-1 receptor signaling. Mol Cancer Ther 1(5): 295-302. Ivy, SP, Wick, JY, Kaufman, BM (2009) An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol 6(10): 569-579. Jain, RK (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7(9): 987-989. Javerzat, S, Auguste, P, Bikfalvi, A (2002) The role of fibroblast growth factors in vascular development. Trends Mol Med 8(10): 483-489. Jawien, J, Nastalek, P, Korbut, R (2004) Mouse models of experimental atherosclerosis. J Physiol Pharmacol 55(3): 503-517. Jones, E, Adcock, IM, Ahmed, BY, Punchard, NA (2007) Modulation of LPS stimulated NF-kappaB mediated Nitric Oxide production by PKCepsilon and JAK2 in RAW macrophages. J Inflamm (Lond) 4: 23. Jubb, AM, Oates, AJ, Holden, S, Koeppen, H (2006) Predicting benefit from anti-angiogenic agents in malignancy. Nature reviews. Cancer 6(8): 626-635. Jukema, JW, Verschuren, JJ, Ahmed, TA, Quax, PH (2011) Restenosis after PCI. Part 1: pathophysiology and risk factors. Nat Rev Cardiol 9(1): 53-62. Kamba, T, McDonald, DM (2007) Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96(12): 1788-1795. Kaneshiro, T, Morioka, T, Inamine, M, Kinjo, T, Arakaki, J, Chiba, I, Sunagawa, N, Suzui, M, Yoshimi, N (2006) Anthraquinone derivative emodin inhibits tumor-associated angiogenesis through inhibition of extracellular signal-regulated kinase 1/2 phosphorylation. Eur J Pharmacol 553(1-3): 46-53. Kim, JB, Han, AR, Park, EY, Kim, JY, Cho, W, Lee, J, Seo, EK, Lee, KT (2007) Inhibition of LPS-induced iNOS, COX-2 and cytokines expression by poncirin through the NF-kappaB inactivation in RAW 264.7 macrophage cells. Biol Pharm Bull 30(12): 2345-2351. Kinsella, BT (2001) Thromboxane A2 signalling in humans: a 'Tail' of two receptors. Biochem Soc Trans 29(Pt 6): 641-654. Knight, B, Katz, DR, Isenberg, DA, Ibrahim, MA, Le Page, S, Hutchings, P, Schwartz, RS, Cooke, A (1992) Induction of adjuvant arthritis in mice. Clin Exp Immunol 90(3): 459-465. Kobayashi, T, Tahara, Y, Matsumoto, M, Iguchi, M, Sano, H, Murayama, T, Arai, H, Oida, H, Yurugi-Kobayashi, T, Yamashita, JK, Katagiri, H, Majima, M, Yokode, M, Kita, T, Narumiya, S (2004) Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest 114(6): 784-794. Kronzon, I, Tunick, PA (2006) Aortic atherosclerotic disease and stroke. Circulation 114(1): 63-75. Kubota, Y (2012) Tumor angiogenesis and anti-angiogenic therapy. Keio J Med 61(2): 47-56. Kwabi-Addo, B, Ozen, M, Ittmann, M (2004) The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer 11(4): 709-724. Kwak, HJ, So, JN, Lee, SJ, Kim, I, Koh, GY (1999) Angiopoietin-1 is an apoptosis survival factor for endothelial cells. FEBS Lett 448(2-3): 249-253. Lambertsen, KL, Biber, K, Finsen, B (2012) Inflammatory cytokines in experimental and human stroke. J Cereb Blood Flow Metab 32(9): 1677-1698. Lang, L (2008) FDA approves sorafenib for patients with inoperable liver cancer. Gastroenterology 134(2): 379. Lange, RA, Flores, ED, Hillis, LD (1991) Restenosis after coronary balloon angioplasty. Annu Rev Med 42: 127-132. Lariviere, R, Moreau, C, Rodrigue, ME, Lebel, M (2004) Thromboxane blockade reduces blood pressure and progression of renal failure independent of endothelin-1 in uremic rats. Prostaglandins Leukot Essent Fatty Acids 71(2): 103-109. Leary, A, Johnston, SR (2007) Small molecule signal transduction inhibitors for the treatment of solid tumors. Cancer Invest 25(5): 347-365. Lee, WY, Kubes, P (2008) Leukocyte adhesion in the liver: distinct adhesion paradigm from other organs. J Hepatol 48(3): 504-512. Lever, A, Mackenzie, I (2007) Sepsis: definition, epidemiology, and diagnosis. BMJ 335(7625): 879-883. Levi, M, van der Poll, T (2010) Inflammation and coagulation. Crit Care Med 38(2 Suppl): S26-34. Li, Y, Yang, KJ, Park, J (2010) Multiple implications of 3-phosphoinositide-dependent protein kinase 1 in human cancer. World J Biol Chem 1(8): 239-247. Libby, P (2002) Atherosclerosis: the new view. Sci Am 286(5): 46-55. Libby, P, Ridker, PM, Maseri, A (2002) Inflammation and atherosclerosis. Circulation 105(9): 1135-1143. Lin, KT, Lien, JC, Chung, CH, Kuo, SC, Huang, TF (2010) A novel compound, NP-184, inhibits the vascular endothelial growth factor induced angiogenesis. Eur J Pharmacol 630(1-3): 53-60. Lin, YC, Lin, JH, Chou, CW, Chang, YF, Yeh, SH, Chen, CC (2008) Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2. Cancer research 68(7): 2375-2383. Liu, AY, Robinson, RR, Hellstrom, KE, Murray, ED, Jr., Chang, CP, Hellstrom, I (1987) Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells. Proc Natl Acad Sci U S A 84(10): 3439-3443. Liu, J, Agarwal, S (2010) Mechanical signals activate vascular endothelial growth factor receptor-2 to upregulate endothelial cell proliferation during inflammation. J Immunol 185(2): 1215-1221. Liu, L, Cao, Y, Chen, C, Zhang, X, McNabola, A, Wilkie, D, Wilhelm, S, Lynch, M, Carter, C (2006) Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66(24): 11851-11858. Liu, YL, Lin, HM, Zou, R, Wu, JC, Han, R, Raymond, LN, Reid, PF, Qin, ZH (2009) Suppression of complete Freund's adjuvant-induced adjuvant arthritis by cobratoxin. Acta Pharmacol Sin 30(2): 219-227. Lloyd-Jones, D, Adams, R, Carnethon, M, De Simone, G, Ferguson, TB, Flegal, K, Ford, E, Furie, K, Go, A, Greenlund, K, Haase, N, Hailpern, S, Ho, M, Howard, V, Kissela, B, Kittner, S, Lackland, D, Lisabeth, L, Marelli, A, McDermott, M, Meigs, J, Mozaffarian, D, Nichol, G, O'Donnell, C, Roger, V, Rosamond, W, Sacco, R, Sorlie, P, Stafford, R, Steinberger, J, Thom, T, Wasserthiel-Smoller, S, Wong, N, Wylie-Rosett, J, Hong, Y (2009a) Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119(3): 480-486. Lloyd-Jones, D, Adams, R, Carnethon, M, De Simone, G, Ferguson, TB, Flegal, K, Ford, E, Furie, K, Go, A, Greenlund, K, Haase, N, Hailpern, S, Ho, M, Howard, V, Kissela, B, Kittner, S, Lackland, D, Lisabeth, L, Marelli, A, McDermott, M, Meigs, J, Mozaffarian, D, Nichol, G, O'Donnell, C, Roger, V, Rosamond, W, Sacco, R, Sorlie, P, Stafford, R, Steinberger, J, Thom, T, Wasserthiel-Smoller, S, Wong, N, Wylie-Rosett, J, Hong, Y (2009b) Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119(3): e21-181. Lu, J, Zhang, K, Nam, S, Anderson, RA, Jove, R, Wen, W (2010) Novel angiogenesis inhibitory activity in cinnamon extract blocks VEGFR2 kinase and downstream signaling. Carcinogenesis 31(3): 481-488. Madonna, R, De Caterina, R (2012) Relevance of new drug discovery to reduce NF-kappaB activation in cardiovascular disease. Vascul Pharmacol 57(1): 41-47. Mates, JM, Perez-Gomez, C, Blanca, M (2000) Chemical and biological activity of free radical 'scavengers' in allergic diseases. Clin Chim Acta 296(1-2): 1-15. Meadows, KN, Bryant, P, Pumiglia, K (2001) Vascular endothelial growth factor induction of the angiogenic phenotype requires Ras activation. J Biol Chem 276(52): 49289-49298. Meadows, TA, Bhatt, DL (2007) Clinical aspects of platelet inhibitors and thrombus formation. Circ Res 100(9): 1261-1275. Medzhitov, R, Janeway, C, Jr. (2000) Innate immunity. N Engl J Med 343(5): 338-344. Michaels, AD, Chatterjee, K (2002) Cardiology patient pages. Angioplasty versus bypass surgery for coronary artery disease. Circulation 106(23): e187-190. Miller, K, Wang, M, Gralow, J, Dickler, M, Cobleigh, M, Perez, EA, Shenkier, T, Cella, D, Davidson, NE (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357(26): 2666-2676. Mitra, S, Abraham, E (2006) Participation of superoxide in neutrophil activation and cytokine production. Biochim Biophys Acta 1762(8): 732-741. Mizia-Stec, K, Zahorska-Markiewicz, B, Goliszek, L (2003) [Adhesion molecules: atherosclerosis and coronary artery disease]. Przegl Lek 60(3): 147-150. Mohan, PS, Spiro, RG (1986) Macromolecular organization of basement membranes. Characterization and comparison of glomerular basement membrane and lens capsule components by immunochemical and lectin affinity procedures. J Biol Chem 261(9): 4328-4336. Moncada, S (1999) Nitric oxide: discovery and impact on clinical medicine. J R Soc Med 92(4): 164-169. Montemurro, F, Valabrega, G, Aglietta, M (2007) Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity. Expert Opin Biol Ther 7(2): 257-268. Moreno, PR, Purushothaman, KR, Sirol, M, Levy, AP, Fuster, V (2006) Neovascularization in human atherosclerosis. Circulation 113(18): 2245-2252. Morin, MJ (2000) From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents. Oncogene 19(56): 6574-6583. Moulton, KS, Heller, E, Konerding, MA, Flynn, E, Palinski, W, Folkman, J (1999) Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation 99(13): 1726-1732. Moulton, KS, Vakili, K, Zurakowski, D, Soliman, M, Butterfield, C, Sylvin, E, Lo, KM, Gillies, S, Javaherian, K, Folkman, J (2003) Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci U S A 100(8): 4736-4741. Moy, B, Kirkpatrick, P, Kar, S, Goss, P (2007) Lapatinib. Nat Rev Drug Discov 6(6): 431-432. Moynagh, PN (2005) The NF-kappaB pathway. J Cell Sci 118(Pt 20): 4589-4592. Mueller, MM, Fusenig, NE (2004) Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 4(11): 839-849. Nathan, C (2002) Points of control in inflammation. Nature 420(6917): 846-852. Nicosia, RF, Ottinetti, A (1990) Growth of microvessels in serum-free matrix culture of rat aorta. A quantitative assay of angiogenesis in vitro. Lab Invest 63(1): 115-122. Noble, ME, Endicott, JA, Johnson, LN (2004) Protein kinase inhibitors: insights into drug design from structure. Science 303(5665): 1800-1805. Nofal, ZM, Soliman, EA, Abd El-Karim, SS, El Zahar, MI, Srour, AM, Sethumadhavan, S, Maher, TJ (2011) Novel benzimidazole derivatives as expected anticancer agents. Acta Pol Pharm 68(4): 519-534. O'Brien, KD, McDonald, TO, Chait, A, Allen, MD, Alpers, CE (1996) Neovascular expression of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in human atherosclerosis and their relation to intimal leukocyte content. Circulation 93(4): 672-682. Olsson, AK, Dimberg, A, Kreuger, J, Claesson-Welsh, L (2006) VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 7(5): 359-371. Osende, JI, Shimbo, D, Fuster, V, Dubar, M, Badimon, JJ (2004) Antithrombotic effects of S 18886, a novel orally active thromboxane A2 receptor antagonist. J Thromb Haemost 2(3): 492-498. Osusky, KL, Hallahan, DE, Fu, A, Ye, F, Shyr, Y, Geng, L (2004) The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis 7(3): 225-233. Pacher, P, Beckman, JS, Liaudet, L (2007) Nitric oxide and peroxynitrite in health and disease. Physiol Rev 87(1): 315-424. Paez, JG, Janne, PA, Lee, JC, Tracy, S, Greulich, H, Gabriel, S, Herman, P, Kaye, FJ, Lindeman, N, Boggon, TJ, Naoki, K, Sasaki, H, Fujii, Y, Eck, MJ, Sellers, WR, Johnson, BE, Meyerson, M (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676): 1497-1500. Paigen, B, Morrow, A, Holmes, PA, Mitchell, D, Williams, RA (1987) Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis 68(3): 231-240. Pan, JS, Hong, MZ | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/15652 | - |
dc.description.abstract | 癌症和粥狀動脈動脈硬化相關的心血管疾病是全球發病率和死亡率的主要原因。由於血管內皮生長因子(VEGF)是誘導腫瘤血管生成和轉移的一個關鍵因素,所以VEGF已成為抗血管新生和癌症治療用藥的有效標的。另一方面,近期文獻顯示thromboxane A2 (TXA2) 受體拮抗劑不僅具有抗血小板作用,同時也具有調節血管內皮細胞功能及粥狀動脈硬化疾病進程之發炎反應。近十年來,在治療癌症,免疫疾病,代謝和感染性疾病的小分子抑制劑趨向蓬勃的發展。然而,研究也指出,標靶抑制VEGF-VEGFR訊息或血小板拮抗劑,具有一定的副作用,如出血或胃腸道併發症,因此發展較少併發症之新穎抑制劑,則可提供更多的新穎治療選擇。在論文的第一部分,我們研究關於benzimidazole 及anthraquinone系列的衍生物,PJ-8及PPemd26在人類臍靜脈內皮細胞(HUVEC)的抗血管新生機制。 PJ-8和PPemd26能有效的抑制內皮細胞的增殖、移行、侵入及血管管腔形成的作用。 此外,在小鼠體內實驗中,PJ-8和PPemd26可以有效抑制VEGF誘導或腫瘤誘導的血管生成作用。我們證實PJ-8和PPemd26對血管生成的抑制作用主要是經由抑制VEGFR2訊息傳導而來的。研究結果顯示,PJ-8和PPemd26,是屬於有效,而不會造成毒性的化合物,可以當作前導結構用來研發更有效的針對抑制VEGFR2訊息傳導途徑的小分子化合物,可用於腫瘤之治療及血管新生相關疾病。在論文的第二部分中,我們發現一種新穎的口服有效之抗血小板藥物,TXA2受體拮抗劑,nstpbp5185,並研究其對於抗血管生成,抗發炎,抗氧化及抗粥狀動脈硬化的作用。 Nstpbp5185能抑制VEGF誘導之血管內皮細胞增殖、移行及血管管腔形成,並抑制主動脈環微血管管腔生成。 nstpbp5185也顯著減少在小鼠體內新生血管形成,抑制發炎過程中大鼠初代主動脈平滑肌細胞的增殖和移行而能減少血管內膜異常增生。此外,nstpbp5185能減少發炎刺激下單核球細胞和巨噬細胞吸附到血管內皮細胞的作用而能減少巨噬細胞浸潤作用。在高膽固醇餵食的Apo E缺陷的粥狀動脈硬化的小鼠動物實驗中,證明nstpbp5185可以減少新生內膜的形成及粥狀動脈硬化的病變區域。在Apo E缺陷的老鼠給藥一個月後進行中大腦動脈阻塞中風模式,發現nstpbp5185能減少腦缺血中風的腦部梗塞面積。 此外,在LPS誘導敗血症或肺栓塞之動物實驗中也都能發現nstpbp5185能有效的增加動物的存活率。在動物實驗中也發現,相較於Aspirin,長期服用nstpbp5185並不會造成胃潰瘍及出血的副作用且不會引發肝功能的損害。綜合研究結果顯示,nstpbp5185可能不僅具有抗血小板的作用,它亦具有抗血管新生、抗發炎、抗氧化的作用並能拮抗粥狀動脈硬化之進程,具有保護血管內皮細胞功能和拮抗動脈粥狀硬化的發炎過程。
對於這些小分子化合物詳細的作用機轉及訊息傳導路徑仍須進一步的研究。目前針對癌症、免疫、血栓、代謝及發炎相關疾病的治療之小分子抑制劑,我們正透過循理設計、藥物動力學和毒理研究來增進這些化合物之作用專一性和藥理活性。 | zh_TW |
dc.description.abstract | Cancers and atherosclerosis-associated cardiovascular diseases are major causes of mortality and morbidity worldwide. As a critical factor in the induction of tumor angiogenesis and metastasis, vascular endothelial growth factor (VEGF) has become an attractive target for anti-angiogenic and cancer therapeutic agents. On the other hand, recent literatures suggest that TP-receptor antagonists not only have antiplatelet effects but also have beneficial effects on endothelial dysfunction and the inflammatory responses involved in atherosclerosis. Recently, the development of small molecule inhibitors in the treatment of cancer, immunological, metabolic and infectious diseases has progressed dramatically. However, several reports indicated that the inhibitors targeting VEGF-VEGFR signaling or anti-platelet agents possess some adverse effects such as bleeding or gastrointestinal complications. Therefore, discovery of new inhibitors with less complications may offer new therapeutic options for the treatment of cancer and atherosclerotic cardiovascular events. In the first part of this study, we have identified two chemicals Pj-8 and PPemd26 from series of benzimidazole and anthraquinone derivatives, respectively, and investigated their anti-angiogenic mechanisms in human umbilical vein endothelial cells (HUVECs). Pj-8 and PPemd26 showed potent inhibitory activity on cell proliferation, migration, invasion, and tube formation of HUVECs. Pj-8 and PPemd26 suppressed VEGF- or tumor-induced angiogenesis in vivo. In addition, we demonstrated that suppression of VEGFR2-mediated signaling contributes to Pj-8 and PPemd26 inhibitory actions on angiogenesis. These results indicate that that Pj-8 and PPemd26 inhibit tumor angiogenesis by targeting the VEGFR2 signaling pathways. They may serve as lead compounds in the development of anti-angiogenic agent in field of cancer and angiogenesis-related diseases. In the second part of this study, we explored and characterized the anti-angiogenic, anti-inflammatory, anti-oxidative and anti-atherosclerotic actions of nstpbp5185, a novel orally selective TP receptor antagonist. Nstpbp5185 inhibited VEGF-induced cell proliferation, migration, invasion, and tube formation of HUVECs and suppressed aorta ring microvessels sprouting. Nstpbp5185 also markedly reduced neovascularization in vivo. Nstpbp5185 also suppressed cell proliferation and migration in rat aorta smooth muscle cells in the inflammation processes, indicating that nstpbp5185 attenuates the neointima formation and restenosis. In addition, nstpbp5185 attenuated monocyte and macrophage adhesion to vascular endothelial cells exposed to inflammatory stimuli, leading to decreased phagocyte infiltration. In the high-cholesterol-diet Apo E-deficient atherosclerosis mouse model, nstpbp5185 was further shown to decrease the neointima formation and aortic atherosclerotic lesion area. Furthermore, nstpbp5185 reduced brain infarction size in an atherosclerosis with MCAO stroke mouse model. Nstpbp5185 also increased survival rate in LPS-induced sepsis model and attenuated pulmonary embolism in pulmonary embolism animal model. Nstpbp5185 has neither gastric ulcerogenic effects, bleeding tendency nor liver damaging effects as compared with aspirin. Collectively, nstpbp5185 possesses pleiotropic pharmacological effects including anti-angiogenic, anti-inflammatory, anti-oxidative and anti-thrombotic activity contributing to its beneficial modulation on endothelial dysfunction, restenosis, atherosclerosis and sepsis.
However, the perspective studies regarding their detail mechanism of action and signal transduction pathway involved are still under investigation. Optimization of these compounds in enhancing its potency and specificity is being pursued through rational design, structure-activity relationship, pharmacokinetics and toxicological studies. | en |
dc.description.provenance | Made available in DSpace on 2021-06-07T17:49:26Z (GMT). No. of bitstreams: 1 ntu-102-D97443001-1.pdf: 5500696 bytes, checksum: bfc5e6290b389e6d4bf6c61a26d92c13 (MD5) Previous issue date: 2013 | en |
dc.description.tableofcontents | 口試委員會審定書………………………………………………………i
誌謝………………………………………………………………………ii 中文摘要………………………………………………………………iv Abstract ………………………………………………………………vi Abbreviations…………………………………………………………ix Part I Chapter 1 Introduction…………………………………………1 Chapter 2 Anti-angiogenic mechanisms of Pj-8, a novel inhibitor of vascular endothelial growth factor receptor signaling ……………………20 Chapter 3 PPemd26, a novel VEGFR2 inhibitor, suppresses angiogenesis and tumor growth………………………………………………………56 Chapter 4 Conclusion and Perspectives………………………………………87 Part II Chapter 1 Introduction………………………………………………………91 Chapter 2 Nstpbp5185, a novel orally selective TP antagonist, attenuates atherosclerotic progression in Apo E-deficient mice model……………………………………………………………120 Chapter 3 Nstpbp5185 reduces neointima formation and atherosclerosis by suppressing the angiogenic and inflammatory signaling pathways…………………………………149 Chapter 4 Inhibition of lipopolysaccharide-induced endotoxemia by nstpbp5185………………………………………………………187 Chapter 5 Conclusion and Perspectives……………………………………217 References….……………………………………………………227 | |
dc.language.iso | en | |
dc.title | 心血管及血管新生相關疾病的治療探討: 化合物Pj-8,PPemd26及nstpbp5185之拮抗作用與機制之探討 | zh_TW |
dc.title | Therapeutic interventions against cardiovascular and angiogenesis-related diseases: the inhibitory effects and mechanisms of novel compounds, Pj-8, PPemd26 and nstpbp5185 | en |
dc.type | Thesis | |
dc.date.schoolyear | 101-1 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 鄧哲明,顏茂雄,楊春茂,吳文彬 | |
dc.subject.keyword | 血管新生,粥狀動脈硬化,血管內膜增生,發炎反應, | zh_TW |
dc.subject.keyword | angiogenesis,atherosclerosis,restenosis,inflammation, | en |
dc.relation.page | 245 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2013-02-01 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥理學研究所 | zh_TW |
顯示於系所單位: | 藥理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-102-1.pdf 目前未授權公開取用 | 5.37 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。